Lu He1,2, Eun-Young Lee1, Nicholas W Sterling1, Lan Kong3, Mechelle M Lewis1,4, Guangwei Du1, Paul J Eslinger1, Xuemei Huang1,4,5,6,7. 1. Department of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey PA, USA. 2. School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China. 3. Department of Public School Health, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA. 4. Department of Pharmacology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA. 5. Department of Radiology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA. 6. Department of Neurosurgery, Pennsylvania State University-Milton S. Hershey Medical Center Hershey, PA, USA. 7. Department of Kinesiology, Pennsylvania State University-Milton S. Hershey Medical Center, Hershey, PA, USA.
Abstract
BACKGROUND: The impact of motor- and non-motor symptoms on health-related quality of life (HRQOL) in Parkinson's disease (PD) has received increasing attention. OBJECTIVES: To address this, the study explored a large cohort of patients enrolled in the PD Biomarker Program. METHODS: The PD Questionnaire-39 (PDQ-39) measured HRQOL, whereas the Unified PD Rating Scale (UPDRS) assessed motor and non-motor symptoms. Determinants of HRQOL in PD patients were identified by stepwise linear regression analysis. The relationship between the PDQ-39 and UPDRS subscale scores then was explored through structural equation modeling. RESULTS: The mean disease duration was 6.8 years and the mean PDQ-39 summary index (PDQ-39SI) was 18.4. UPDRS-I (non-motor function) and UPDRS-II (motor questionnaire) scores demonstrated the strongest correlations with PDQ-39SI (r Ϡ 0.4, P < 0.05), whereas UPDRS-III (motor exam) and UPDRS-IV (motor complications) scores were correlated moderately with PDQ-39SI (0.3 < r < 0.4, P < 0.05). Multiple linear stepwise regression analyses showed that age (β= -0.13, P < 0.001), education (β= -0.07, P = 0.008), UPDRS-I (β= 0.32, P = 0.000), and UPDRS-II (β= 0.44, P < 0.001) significantly contributed to HRQOL, and cumulatively accounted for 69.1% of the PDQ-39SI variance. UPDRS-II score was the primary predictor of PDQ-39SI, accounting for 57.3% of the variance, whereas UPDRS-I score accounted for 7.5%. UPDRS-III and -IV and other factors measured did not survive stepwise regression. Structural equation modeling confirmed the association of UPDRS-II (β= 0.67, P < 0.001) and UPDRS-I (β= 0.35, P < 0.001) with the PDQ-39SI. CONCLUSION: Both motor and non-motor function scores impacted significantly HRQOL in PD. UPDRS-III, however, has limited contributions to HRQOL although it is used as a main outcome in many clinical trials.
BACKGROUND: The impact of motor- and non-motor symptoms on health-related quality of life (HRQOL) in Parkinson's disease (PD) has received increasing attention. OBJECTIVES: To address this, the study explored a large cohort of patients enrolled in the PD Biomarker Program. METHODS: The PD Questionnaire-39 (PDQ-39) measured HRQOL, whereas the Unified PD Rating Scale (UPDRS) assessed motor and non-motor symptoms. Determinants of HRQOL in PDpatients were identified by stepwise linear regression analysis. The relationship between the PDQ-39 and UPDRS subscale scores then was explored through structural equation modeling. RESULTS: The mean disease duration was 6.8 years and the mean PDQ-39 summary index (PDQ-39SI) was 18.4. UPDRS-I (non-motor function) and UPDRS-II (motor questionnaire) scores demonstrated the strongest correlations with PDQ-39SI (r Ϡ 0.4, P < 0.05), whereas UPDRS-III (motor exam) and UPDRS-IV (motor complications) scores were correlated moderately with PDQ-39SI (0.3 < r < 0.4, P < 0.05). Multiple linear stepwise regression analyses showed that age (β= -0.13, P < 0.001), education (β= -0.07, P = 0.008), UPDRS-I (β= 0.32, P = 0.000), and UPDRS-II (β= 0.44, P < 0.001) significantly contributed to HRQOL, and cumulatively accounted for 69.1% of the PDQ-39SI variance. UPDRS-II score was the primary predictor of PDQ-39SI, accounting for 57.3% of the variance, whereas UPDRS-I score accounted for 7.5%. UPDRS-III and -IV and other factors measured did not survive stepwise regression. Structural equation modeling confirmed the association of UPDRS-II (β= 0.67, P < 0.001) and UPDRS-I (β= 0.35, P < 0.001) with the PDQ-39SI. CONCLUSION: Both motor and non-motor function scores impacted significantly HRQOL in PD. UPDRS-III, however, has limited contributions to HRQOL although it is used as a main outcome in many clinical trials.
Entities:
Keywords:
Parkinson’s disease; Unified Parkinson’s disease rating scales; motor symptoms; non-motor symptoms; quality of life; review; structural equation modeling; structure
Authors: Sotirios A Parashos; Sheng Luo; Kevin M Biglan; Ivan Bodis-Wollner; Bo He; Grace S Liang; G Webster Ross; Barbara C Tilley; Lisa M Shulman Journal: JAMA Neurol Date: 2014-06 Impact factor: 18.302
Authors: Sze-Ee Soh; Jennifer L McGinley; Jennifer J Watts; Robert Iansek; Anna T Murphy; Hylton B Menz; Frances Huxham; Meg E Morris Journal: Qual Life Res Date: 2012-10-16 Impact factor: 4.147
Authors: Mayela Rodríguez-Violante; Amin Cervantes-Arriaga; Teresa Corona; Daniel Martínez-Ramírez; Hugo Morales-Briceño; Pablo Martínez-Martín Journal: Arch Med Res Date: 2013-01-30 Impact factor: 2.235
Authors: Katrina Gwinn; Karen K David; Christine Swanson-Fischer; Roger Albin; Coryse St Hillaire-Clarke; Beth-Anne Sieber; Codrin Lungu; F DuBois Bowman; Roy N Alcalay; Debra Babcock; Ted M Dawson; Richard B Dewey; Tatiana Foroud; Dwight German; Xuemei Huang; Vlad Petyuk; Judith A Potashkin; Rachel Saunders-Pullman; Margaret Sutherland; David R Walt; Andrew B West; Jing Zhang; Alice Chen-Plotkin; Clemens R Scherzer; David E Vaillancourt; Liana S Rosenthal Journal: Biomark Med Date: 2017-06-23 Impact factor: 2.851
Authors: Junchao Shen; Noor Amari; Rebecca Zack; R Tyler Skrinak; Travis L Unger; Marijan Posavi; Thomas F Tropea; Sharon X Xie; Vivianna M Van Deerlin; Richard B Dewey; Daniel Weintraub; John Q Trojanowski; Alice S Chen-Plotkin Journal: Ann Neurol Date: 2022-06-07 Impact factor: 11.274
Authors: Mechelle M Lewis; Guangwei Du; Jennifer Baccon; Amanda M Snyder; Ben Murie; Felicia Cooper; Christy Stetter; Lan Kong; Christopher Sica; Richard B Mailman; James R Connor; Xuemei Huang Journal: Mov Disord Date: 2018-05-14 Impact factor: 10.338
Authors: Ming Wang; Zheng Li; Eun Young Lee; Mechelle M Lewis; Lijun Zhang; Nicholas W Sterling; Daymond Wagner; Paul Eslinger; Guangwei Du; Xuemei Huang Journal: BMC Med Res Methodol Date: 2017-09-25 Impact factor: 4.615